Aptevo Therapeutics Inc. · GETTEX:AP82

Aptevo Therapeutics Inc. financial statements

Aptevo Therapeutics Inc.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue0003.11M12.3M4.31M32.4M23.1M14.7M9.98M
Cost of revenue240.0K352.0K17.1M17.9M19.0M17.9M19.9M11.2M5.01M12.5M
Gross profit-240.0K-352.0K-567.0K3.11M12.3M-13.5M-2.23M11.9M9.65M12.3M
Research and development14.5M14.4M17.1M17.9M19.0M17.9M24.8M35.4M29.0M29.1M
Selling, general and administrative11.8M10.2M11.8M13.9M14.7M14.0M25.3M28.1M34.6M36.2M
Operating income-26.3M-24.6M-28.9M-28.6M-21.4M-27.5M-41.0M-51.7M-53.9M-138.8M
Depreciation and amortization240.0K352.0K567.0K901.0K1.14M1.41M2.23M2.39M3.13M3.36M
EBITDA-26.1M-24.3M-28.3M-27.7M-20.3M-26.1M-38.7M-49.3M-50.8M-135.4M
Interest expense35.7M7.06M00000
Income before tax-26.0M-24.1M-18.6M7.01M-29.4M-30.9M-43.1M-53.7M-55.9M-139.6M
Income tax0-1.24M-35.7M-2.10M-12.5M-2.62M-23.3M-23.3M-19.7M
Net income-26.0M-24.1M-17.4M8.03M-28.5M-17.8M-40.4M-53.7M6.97M-112.4M
Earnings per share, basic-87.27-31,460.23-2,316.831.57-6.07-5.23-13.86-2.390.33-5.55
Earnings per share, diluted-87.27-31,460.23-2,316.831.57-6.07-5.23-13.86-2.390.33-5.55

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents21.6M8.71M16.9M22.6M45.0M40.0M12.4M30.6M7.09M9.68M
Short-term investments73.7M73.7M44.8M
Receivables2.50M3.66M2.37M7.02M5.22M2.14M307.0K
Inventory1.57M3.08M4.78M6.14M1.78M1.03M461.0K
Current assets23.1M10.7M19.1M27.4M52.6M47.3M30.0M48.7M95.1M71.4M
Property, plant and equipment303.0K543.0K895.0K1.46M2.38M2.81M3.95M5.20M5.84M5.91M
Goodwill00
Total assets27.2M15.6M24.8M34.2M56.6M53.5M53.4M67.5M117.0M91.9M
Accounts payable877.0K1.24M3.98M3.50M3.46M5.58M6.43M11.7M7.35M10.5M
Current liabilities6.05M6.21M7.22M8.71M34.8M14.5M38.2M17.6M18.5M19.5M
Long-term debt1.46M3.71M20.1M19.3M15.7M18.4M
Total debt4.63M4.63M04.01M16.0M28.2M19.9M19.3M19.1M18.4M
Total liabilities9.81M10.8M12.6M16.2M55.4M37.0M41.6M37.1M35.0M41.3M
Shareholders' equity17.4M4.75M12.2M18.0M1.22M16.6M11.8M30.4M82.0M50.6M
Shares outstanding997.8K4.05K12.0K6.47M4.90M4.41M3.23M22.8M21.6M20.3M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-25.6M-23.8M-11.7M-21.0M-21.7M-29.3M-42.4M-51.4M-41.6M-36.9M
Capital spending000-29.0K-713.0K-88.0K-153.0K-976.0K-1.40M-2.51M
Free cash flow-25.6M-23.8M-11.7M-21.1M-22.4M-29.4M-42.5M-52.4M-43.0M-39.4M
Cash from investing000-29.0K-713.0K28.0M4.10M72.8M29.5M-47.4M
Cash from financing38.5M15.6M6.00M-2.62M26.2M23.9M20.1M-787.0K19.5M89.3M
Dividends paid-1.57M-4.00K-10.2M-21.2M-58.0K00
Share buybacks-10.0K-4.00K10.2M-11.0K-58.0K-758.0K-758.0K38.0K
Change in cash12.9M-8.19M-5.73M-23.7M3.77M22.6M-18.1M20.6M7.42M5.04M